The study compound is being developed for the treatment of type 2 diabetes and weight control by lowering blood sugar levels. People with type 2 diabetes have too much sugar in their blood and need treatment to control their sugar levels. The study compound acts like a hormone that occurs naturally in the body. This hormone helps people feel full and helps to lower blood sugar levels. Some medications that act this way are already approved and being used to treat people living with diabetes and for weight control. The study compound can be administered more easily than those medications, because those medications are administered with an injection under the skin while the study compound can be given by mouth.

In this study we will investigate how quickly and to what extent the study compound is absorbed, transported, and eliminated from the body. In addition, we will look at the substances in the blood that are produced when the study compound is broken down by the body (known as breakdown products) and we will ask you to assess the taste of the study compound in tablet and capsule form. Furthermore, we will also investigate tablets that contain different particles sizes. We will also investigate how safe the study compound is and how well it is tolerated when it is used by healthy people.

The compound has already been tested in healthy individuals and patients with type 2 diabetes. In these clinical trials, the following side-effects were observed most often: nausea, vomiting and diarrhea. In general, these side effects were not considered severe. You may also experience other, yet unknown, side effects. Prior to the medical screening, you will receive written information about the trial, which also describes the possible side effects. This information will also be discussed with you at the start of the medical screening. You can then ask questions to the screening physician or nurse. Once everything is clear to you, you can decide to give written consent to participate in the trial. The medical screening will only take place after you have given written consent to participate in the trial. We want to emphasize that even after giving written consent, participation in any clinical trial is voluntary. You can decide at any time not to participate or to stop the medical screening or the trial. You do not need to provide a reason for why you no longer wish to participate.

• You are a healthy male or female.
• You are at least 18 and at most 65 years old.
• Your weight is at least 50 kg and your Body Mass Index (BMI) is at least 23.0 and at most 32.0 kg/m². The BMI shows the relationship between body weight in kilograms and height in meters.
• Both non-smokers and light smokers or occasional smokers (max. 5 cigarettes per day) are allowed to participate in this clinical trial. During your stay in our research facility you are not allowed to smoke.

Note:

• You cannot participate in the trial if you have participated in another clinical trial in the 90 days prior to the first compound administration in this clinical trial (counting from the follow-up visit from the previous study).
• To determine if you are suitable to participate in this trial, you will undergo a medical screening. Depending on availability, this can be performed in Groningen or in Utrecht.
• As a female you can only participate if you are not pregnant, not breast feeding and meet one of the following conditions:
  • You are using hormonal contraception (for example an intra-uterine device containing hormones) in combination with a condom. Please note: hormonal contraception taken by mouth (for example the contraceptive pill) is not allowed in this trial.
  • You are using a copper intra-uterine device in combination with a condom;
  • You have passed the menopause (no periods for at least 12 months);
  • You have been sterilized or your male partner has been sterilized;
  • You are only sexually active with a partner of the same sex;
  • You are not sexually active according to your lifestyle.
• As a male no contraception measures are needed.

The trial consists of 3 periods in which you will stay in the research facility in Groningen for a minimum of 17 days (16 nights) and a maximum of 25 days (24 nights) during the first two periods. The duration of these periods of stay is dependent on how you respond to the study compound. After the second period it will be decided whether the third period will continue or the study will stop. If the third does continue, you will stay in the research facility in Groningen for 6 days (5 nights). The follow-up visit will take place 12 to 16 days after the last departure from the research facility.

Note: You must be available for all dates to be able to participate in this clinical trial.